Cargando…
Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody
BACKGROUND: Patients with interstitial lung disease (ILD) are occasionally positive for anti-neutrophil cytoplasmic antibodies (ANCAs). Differences between ILDs secondary to microscopic polyangiitis (MPA) and isolated ANCA-positive idiopathic interstitial pneumonia (IIP) remain unclear. The aim of t...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7968287/ https://www.ncbi.nlm.nih.gov/pubmed/33726733 http://dx.doi.org/10.1186/s12890-021-01451-4 |
_version_ | 1783666033548066816 |
---|---|
author | Sun, Xin Peng, Min Zhang, Ting Li, Zongru Song, Lan Li, Mengtao Shi, Juhong |
author_facet | Sun, Xin Peng, Min Zhang, Ting Li, Zongru Song, Lan Li, Mengtao Shi, Juhong |
author_sort | Sun, Xin |
collection | PubMed |
description | BACKGROUND: Patients with interstitial lung disease (ILD) are occasionally positive for anti-neutrophil cytoplasmic antibodies (ANCAs). Differences between ILDs secondary to microscopic polyangiitis (MPA) and isolated ANCA-positive idiopathic interstitial pneumonia (IIP) remain unclear. The aim of this study was to explore the differences in clinical features and outcomes between MPA-associated ILDs and isolated ANCA-positive IIPs. METHODS: We reviewed 1338 ILDs patients with available ANCA results and retrospectively analysed 80 patients who were ANCA-positive. MPA-associated ILDs (MPA-ILDs group) and isolated ANCA-positive IIPs (ANCA-IIPs group) were compared. RESULTS: Among 80 patients with ANCA-positive ILDs, 31 (38.75%) had MPA-ILDs, and 49 (61.25%) had isolated ANCA-positive IIPs. Compared with ANCA-IIPs group, patients in MPA-ILDs group had a higher proportion of fever (p = 0.006) and higher neutrophil count (p = 0.011), erythrocyte sedimentation rate (ESR) (p < 0.001) and C-reactive protein (CRP) (p = 0.005). Multivariable analysis showed that ESR level was an independent risk factor for mortality in all 80 ANCA-positive ILDs patients (HR 1.028, p = 0.001). Survival in MPA-ILDs group was lower than that in ANCA-IIPs group, and further stratified analysis revealed that ANCA-IIPs patients with elevated ESR or CRP had a worse prognosis than those with normal inflammation markers, with 5-year cumulative survival rates of 60.00%, 86.90% and 100.00% in MPA-ILDs and ANCA-IIPs with and without elevated inflammation markers, respectively. CONCLUSIONS: Among patients with ANCA-positive ILDs, the prognoses of ANCA-IIPs with normal inflammation markers, ANCA-IIPs with elevated inflammation markers and MPA-ILDs were sequentially poorer. Therefore, stratified treatment should be considered in the management of ILDs patients positive for ANCAs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-021-01451-4. |
format | Online Article Text |
id | pubmed-7968287 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-79682872021-03-19 Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody Sun, Xin Peng, Min Zhang, Ting Li, Zongru Song, Lan Li, Mengtao Shi, Juhong BMC Pulm Med Research Article BACKGROUND: Patients with interstitial lung disease (ILD) are occasionally positive for anti-neutrophil cytoplasmic antibodies (ANCAs). Differences between ILDs secondary to microscopic polyangiitis (MPA) and isolated ANCA-positive idiopathic interstitial pneumonia (IIP) remain unclear. The aim of this study was to explore the differences in clinical features and outcomes between MPA-associated ILDs and isolated ANCA-positive IIPs. METHODS: We reviewed 1338 ILDs patients with available ANCA results and retrospectively analysed 80 patients who were ANCA-positive. MPA-associated ILDs (MPA-ILDs group) and isolated ANCA-positive IIPs (ANCA-IIPs group) were compared. RESULTS: Among 80 patients with ANCA-positive ILDs, 31 (38.75%) had MPA-ILDs, and 49 (61.25%) had isolated ANCA-positive IIPs. Compared with ANCA-IIPs group, patients in MPA-ILDs group had a higher proportion of fever (p = 0.006) and higher neutrophil count (p = 0.011), erythrocyte sedimentation rate (ESR) (p < 0.001) and C-reactive protein (CRP) (p = 0.005). Multivariable analysis showed that ESR level was an independent risk factor for mortality in all 80 ANCA-positive ILDs patients (HR 1.028, p = 0.001). Survival in MPA-ILDs group was lower than that in ANCA-IIPs group, and further stratified analysis revealed that ANCA-IIPs patients with elevated ESR or CRP had a worse prognosis than those with normal inflammation markers, with 5-year cumulative survival rates of 60.00%, 86.90% and 100.00% in MPA-ILDs and ANCA-IIPs with and without elevated inflammation markers, respectively. CONCLUSIONS: Among patients with ANCA-positive ILDs, the prognoses of ANCA-IIPs with normal inflammation markers, ANCA-IIPs with elevated inflammation markers and MPA-ILDs were sequentially poorer. Therefore, stratified treatment should be considered in the management of ILDs patients positive for ANCAs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-021-01451-4. BioMed Central 2021-03-16 /pmc/articles/PMC7968287/ /pubmed/33726733 http://dx.doi.org/10.1186/s12890-021-01451-4 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Sun, Xin Peng, Min Zhang, Ting Li, Zongru Song, Lan Li, Mengtao Shi, Juhong Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody |
title | Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody |
title_full | Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody |
title_fullStr | Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody |
title_full_unstemmed | Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody |
title_short | Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody |
title_sort | clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7968287/ https://www.ncbi.nlm.nih.gov/pubmed/33726733 http://dx.doi.org/10.1186/s12890-021-01451-4 |
work_keys_str_mv | AT sunxin clinicalfeaturesandlongtermoutcomesofinterstitiallungdiseasewithantineutrophilcytoplasmicantibody AT pengmin clinicalfeaturesandlongtermoutcomesofinterstitiallungdiseasewithantineutrophilcytoplasmicantibody AT zhangting clinicalfeaturesandlongtermoutcomesofinterstitiallungdiseasewithantineutrophilcytoplasmicantibody AT lizongru clinicalfeaturesandlongtermoutcomesofinterstitiallungdiseasewithantineutrophilcytoplasmicantibody AT songlan clinicalfeaturesandlongtermoutcomesofinterstitiallungdiseasewithantineutrophilcytoplasmicantibody AT limengtao clinicalfeaturesandlongtermoutcomesofinterstitiallungdiseasewithantineutrophilcytoplasmicantibody AT shijuhong clinicalfeaturesandlongtermoutcomesofinterstitiallungdiseasewithantineutrophilcytoplasmicantibody |